UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market (2025-2030)
The UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market was valued at $132.88 Million in 2025 and projected to reach to $222.17 Million by 2030, representing a compound annual growth rate of 10.8%. The UK HPV Test and Pap Smear market is poised for sustained expansion through 2030, driven by NHS modernisation initiatives and the transition towards HPV-primary screening protocols.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market Trends and Insights
- The UK market benefits from strong healthcare infrastructure, widespread cervical screening programmes, and increasing awareness of HPV-related cancers among the population.
- The UK's National Health Service (NHS) continues to expand access to HPV testing and cervical screening, driving market expansion across both public and private healthcare sectors. In the UK, the shift towards HPV-based testing over traditional Pap smears reflects evolving clinical guidelines and improved diagnostic accuracy.
- The UK market is characterized by rising demand for preventive healthcare, growing adoption of liquid-based cytology, and increased investment in women's health initiatives.
- Between 2025 and 2030, the UK is expected to see enhanced screening coverage, particularly in underserved regions, alongside technological advancements in HPV detection methods that improve patient outcomes and reduce healthcare costs..
Key Market Statistics
- CAGR (2025-2030) 10.8% CAGR
- Market Size, 2025 ~USD 132.88 Million
- Forecast, 2030 ~USD 222.17 Million
- Country UK
UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market Overview
Market Valuation :
The UK HPV Test and Pap Smear market is valued at £132.88 million in 2025, with strong growth trajectory driven by NHS cervical screening initiatives and increased preventive healthcare spending.
Robust Growth Rate :
The UK market is expanding at a CAGR of 10.8% from 2025 to 2030, outpacing the global average of 10%, reflecting heightened demand for cervical cancer screening and HPV detection technologies.
NHS Screening Programmes :
The UK's established National Health Service cervical screening programme provides systematic population coverage, ensuring consistent demand for HPV tests and Pap smears across all regions and demographics.
Healthcare Infrastructure :
Advanced laboratory facilities, digital pathology adoption, and integration of HPV testing into primary care settings strengthen the UK market's competitive position and accessibility for patients.
UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market Dynamics
- Increasing awareness of HPV-related cancers, coupled with government investment in preventive healthcare, will accelerate adoption rates across primary care and specialist centres.
- The market will benefit from technological advancements in liquid-based cytology and molecular testing platforms. Key growth catalysts include rising cervical cancer prevention awareness, integration of HPV testing into routine screening programmes, and expansion of screening eligibility criteria.
- Private healthcare providers and diagnostic laboratories will capitalise on growing demand, while NHS procurement of advanced testing solutions will drive volume growth.
- By 2030, the market is expected to reach £222.17 million, reflecting the UK's commitment to cervical cancer elimination and improved patient outcomes..
Related Ecosystem
In Vitro Diagnostics
- Polymerase Chain Reaction (PCR)
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Dna Microarrays
- Assay Kits
- Microarrays
- ROCHE HOLDINGS AG
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Abbott Laboratories
- Biomerieux s.a.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- The UK HPV Test and Pap Smear Market is valued at £132.88 million in 2025 and will reach £222.17 million by 2030, growing at 10.8% CAGR.
- The UK's NHS-led cervical screening programmes and shift towards HPV-based testing are primary drivers of market growth.
- The UK market is experiencing increased adoption of liquid-based cytology and advanced HPV detection technologies.
- Enhanced screening coverage and preventive healthcare initiatives in the UK will support sustained market expansion through 2030.
Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | VAGINAL CANCER SCREENING (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 10% from 2025 to 2030 |
| Largest Segment | CERVICAL CANCER SCREENING (Application) |
| Market Size Base Year (Billions) | ~USD 2.45 (2025) |
| Revenue Forecast (Billions) | ~USD 3.94 (2030) |
| Segments Covered | Product & Service, Test Type, Type, Technology, Application, Care Setting |
UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report Segmentation
6 segment dimensions are covered across the global market.
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Hpv Testing
- Pap Tests
By Type
- Co-Testing
- Follow-Up Hpv Testing
- Primary Hpv Testing
By Technology
- Cytology
- Immunodiagnostics
- Molecular Diagnostics
By Application
- Cervical Cancer Screening
- Vaginal Cancer Screening
By Care Setting
- Diagnostic Laboratories
- Hospitals
- Physicians’ Offices & Clinics
UK: HPV TESTING AND PAP TEST MARKET, BY APPLICATION, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CERVICAL CANCER SCREENING | 107.1 | 114.2 | 122.7 | 133.1 | 146 | 161.7 | 180.5 | 204 | 10.7 |
| VAGINAL CANCER SCREENING | 8.6 | 9.3 | 10.1 | 11.2 | 12.4 | 14 | 15.8 | 18.2 | 12.4 |
| TOTAL | 115.7 | 123.5 | 132.9 | 144.3 | 158.4 | 175.7 | 196.3 | 222.2 | 10.8 |
Target Audience
- Diagnostic Laboratory Operators : UK-based pathology labs and diagnostic centres need market intelligence to optimise HPV testing capacity, invest in automation, and align service offerings with NHS screening programme requirements and private demand.
- Medical Device & IVD Manufacturers : Global and UK diagnostic companies require detailed market data to assess UK market potential, plan product registrations, negotiate NHS contracts, and develop region-specific commercialisation strategies.
- Healthcare Investors & PE Firms : Investment professionals evaluating UK healthcare assets need comprehensive market sizing and growth forecasts to identify acquisition targets, assess portfolio company performance, and evaluate exit opportunities.
- NHS Procurement & Policy Teams : NHS England and regional health authorities use market research to inform screening programme budgets, technology procurement decisions, and evidence-based policy development for cervical cancer prevention.
- Private Healthcare Providers : UK private clinics and women's health centres require market insights to understand demand trends, competitive positioning, pricing strategies, and growth opportunities in the expanding private cervical screening sector.
Key Companies in the UK Human Papilloma Virus/HPV Test and Pap Smear/Test Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BIOMERIEUX S.A. | France | Public Company | Microbiology & AST (VITEK 2, VITEK MS, VITEK REVEAL, API, ETEST, CHROMID, culture media),Molecular & Syndromic (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, BIOMERIEUX EPISEQ CS),Immunoassay & Sepsis (VIDAS, Hybiome CLIA), |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumer Products,Corporate Assurance,Health and Safety, |
| QUIDEL CORPORATION | United States | Public Company | Labs (clinical chemistry and immunoassay),Transfusion Medicine,Point of Care, |
| HOLOGIC, INC. | United States | Private Company | Diagnostics (Aptima, Panther, ThinPrep, viral load, SARS-CoV-2),Breast Health (3D mammography, biopsy, localization, software),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa, CoolSeal), |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and molecular diagnostics assays,PCR and digital PCR solutions, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and single-use solutions),Life Sciences (research tools and genomic medicines),Diagnostics (clinical instruments and consumables), |
| ABBOTT | United States | Public Company | Medical Devices,Diagnostic Products,Nutritional Products, |
| SEEGENE INC. | South Korea | Public Company | Respiratory infectious disease panels,Sexually transmitted infection and HPV assays,Gastrointestinal and meningitis syndromic panels, |
| SD BIOSENSOR, INC. | South Korea | Public Company | STANDARD Q rapid diagnostics,STANDARD F fluorescence immunodiagnostics,STANDARD E enzyme immunoassay, |
| SANSURE BIOTECH INC. | China | Public Company | Nucleic acid diagnostic reagents (respiratory, HPV, reproductive, blood-borne, GI, others),Rapid antigen tests,Nucleic acid extraction and purification kits, sample reagents, |
| MOLBIO DIAGNOSTICS LIMITED | India | Private Company | Truenat PCR platforms (instruments),Truenat assays and reagents,Disposable POCT devices (dengue, malaria, COVID-19, others), |
BIOMERIEUX S.A.
bioMérieux S.A. is a French public company founded in 1963 that employs 14,894 people. The company specializes in in vitro diagnostics and microbiology testing solutions.
INTERTEK GROUP PLC
Intertek Group PLC is a British public company established in 1885 with 45,425 employees. The company offers testing, inspection, and certification services across multiple industries.
QUIDEL CORPORATION
Quidel Corporation is a United States public company founded in 1979 with 6,500 employees. The company manufactures rapid diagnostic testing products and molecular assays.
HOLOGIC, INC.
Hologic, Inc. is a private United States company founded in 1985 with 7,070 employees. The company develops and manufactures diagnostic and medical imaging products.
QIAGEN
QIAGEN is a Dutch public company founded in 1984 with 5,500 employees. The company provides molecular diagnostics, sample preparation, and life sciences research tools.
DANAHER CORPORATION
Danaher Corporation is a United States public company founded in 1969 with 59,000 employees. The company operates across diagnostics, life sciences, and environmental solutions.
ABBOTT
Abbott is a United States public company founded in 1888 with 115,000 employees. The company is a diversified healthcare company providing diagnostics, medical devices, and pharmaceuticals.
SEEGENE INC.
Seegene Inc. is a South Korean public company founded in 2000 with 216 employees. The company specializes in molecular diagnostic testing and multiplex PCR technology.
SD BIOSENSOR, INC.
SD Biosensor, Inc. is a South Korean public company founded in 1999 with 576 employees. The company develops and manufactures rapid diagnostic test kits and point-of-care devices.
SANSURE BIOTECH INC.
Sansure Biotech Inc. is a Chinese public company founded in 2008 with 2,128 employees. The company develops molecular diagnostic reagents and testing solutions.
MOLBIO DIAGNOSTICS LIMITED
Molbio Diagnostics Limited is a private Indian company founded in 2000. The company develops and manufactures molecular diagnostic devices and testing solutions.
Reasons to Buy this Report
- Market Size & Growth Data : Access precise UK market valuations (£132.88M in 2025, £222.17M in 2030) and 10.8% CAGR forecasts to inform investment decisions, product launches, and market entry strategies specific to the UK healthcare landscape.
- NHS Integration Insights : Understand how NHS cervical screening programmes influence market dynamics, procurement cycles, and reimbursement pathways, enabling strategic positioning within the UK's largest healthcare buyer.
- Competitive Landscape Analysis : Identify UK-specific market players, diagnostic technology adoption rates, and regional variations in HPV testing preferences to benchmark performance and identify partnership opportunities.
- Regulatory & Policy Context : Gain clarity on UK regulatory requirements, NICE guidance, and screening programme updates that directly impact product approvals, market access, and reimbursement eligibility for HPV and Pap tests.
- Growth Opportunity Mapping : Discover high-potential segments within the UK market, including primary care expansion, private sector growth, and emerging technologies, to prioritise resource allocation and maximise ROI.
Frequently asked questions
What is the current market size of the HPV Test and Pap Smear market in the UK?
The UK HPV Test and Pap Smear Market is valued at £132.88 million in 2025.
What is the projected market size for the UK HPV Test and Pap Smear market by 2030?
The UK market is projected to reach £222.17 million by 2030.
What is the CAGR for the UK HPV Test and Pap Smear market?
The UK market is expected to grow at a compound annual growth rate of 10.8% between 2025 and 2030.
What are the main drivers of growth in the UK HPV Test and Pap Smear market?
Key drivers include NHS cervical screening programmes, the shift towards HPV-based testing, increased awareness of HPV-related cancers, and growing adoption of advanced diagnostic technologies in the UK.
How is the UK market transitioning from Pap smears to HPV testing?
The UK is experiencing a clinical shift towards HPV-based testing due to improved diagnostic accuracy, better patient outcomes, and updated NHS guidelines that prioritize HPV detection over traditional Pap smear methods.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the global HPV testing and Pap test market.
Exhaustive secondary research was done to collect information on the HPV testing and Pap test market. The next step was to validate these findings, assumptions, and sizes with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the HPV testing and Pap test market.
Four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Note 1: Others include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = > USD 100 million, tier 2 = USD 10 million to USD 100 million, and tier 3 = < USD 10 million
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both the top-down and bottom-up approaches were used to estimate and validate the HPV testing and Pap test market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size included the following:
- The key players in the industry have been identified through extensive secondary research.
- The revenues generated by leading players operating in the HPV testing and Pap test market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size included the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Human Papillomavirus (HPV) testing identifies the presence of high-risk HPV strains that can lead to cervical cancer and related abnormalities. It is increasingly adopted as a primary screening approach, either independently or alongside Pap testing (co-testing), to assess the risk of cervical disease.
The Papanicolaou (Pap) test is a cytological screening procedure used to detect precancerous and cancerous cells in the cervix, which connects the uterus and vagina. While primarily applied in cervical cancer screening, Pap tests can also detect abnormal or malignant cells in the vaginal canal in some cases.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global HPV testing and Pap test market by product & service, test type, technology, application, care setting, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall HPV testing and Pap test market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the HPV testing and Pap test market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region
Get the Full Human Papilloma Virus/HPV Test and Pap Smear/Test Market Report
Full forecast, segment splits, and company analysis for all Human Papilloma Virus/HPV Test and Pap Smear/Test Market.
- US Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Canada Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Germany Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- France Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Italy Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Spain Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- China Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Japan Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- India Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Brazil Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Mexico Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Saudi Arabia Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- UAE Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Europe Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Asia Pacific Human Papilloma Virus/HPV Test and Pap Smear/Test Market
- Rest Of Latam Human Papilloma Virus/HPV Test and Pap Smear/Test Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
